Literature DB >> 11859030

Recombinant human parathyroid hormone.

Jonathan Reeve.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11859030      PMCID： PMC1122377          DOI： 10.1136/bmj.324.7335.435

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  13 in total

Review 1.  PTH: a future role in the management of osteoporosis?

Authors:  J Reeve
Journal:  J Bone Miner Res       Date:  1996-04       Impact factor: 6.741

2.  Parathyroid hormone and experimental osteosclerosis.

Authors:  D N Kalu; F H Doyle; J Pennock; G V Foster
Journal:  Lancet       Date:  1970-06-27       Impact factor: 79.321

3.  Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride.

Authors:  J Reeve; U M Davies; R Hesp; E McNally; D Katz
Journal:  BMJ       Date:  1990-08-11

4.  Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.

Authors:  B L Riggs; S F Hodgson; W M O'Fallon; E Y Chao; H W Wahner; J M Muhs; S L Cedel; L J Melton
Journal:  N Engl J Med       Date:  1990-03-22       Impact factor: 91.245

5.  Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.

Authors:  F Cosman; J Nieves; L Woelfert; C Formica; S Gordon; V Shen; R Lindsay
Journal:  J Bone Miner Res       Date:  2001-05       Impact factor: 6.741

6.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

Authors:  R M Neer; C D Arnaud; J R Zanchetta; R Prince; G A Gaich; J Y Reginster; A B Hodsman; E F Eriksen; S Ish-Shalom; H K Genant; O Wang; B H Mitlak
Journal:  N Engl J Med       Date:  2001-05-10       Impact factor: 91.245

7.  Treatment with parathyroid peptides and estrogen replacement for severe postmenopausal vertebral osteoporosis: prediction of long-term responses in spine and femur.

Authors:  J Reeve; A Mitchell; M Tellez; P Hulme; J R Green; B Wardley-Smith; R Mitchell
Journal:  J Bone Miner Metab       Date:  2001       Impact factor: 2.626

8.  Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis.

Authors:  J Reeve; R Hesp; D Williams; P Hulme; L Klenerman; J M Zanelli; A J Darby; G W Tregear; J A Parsons
Journal:  Lancet       Date:  1976-05-15       Impact factor: 79.321

9.  Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial.

Authors:  N E Lane; S Sanchez; G W Modin; H K Genant; E Pierini; C D Arnaud
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

10.  Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial.

Authors:  J Reeve; P J Meunier; J A Parsons; M Bernat; O L Bijvoet; P Courpron; C Edouard; L Klenerman; R M Neer; J C Renier; D Slovik; F J Vismans; J T Potts
Journal:  Br Med J       Date:  1980-06-07
View more
  8 in total

1.  Recombinant human parathyroid hormone. Preclinical data on rat osteosarcoma were not dismissed.

Authors:  Gemma Kuijpers; Bruce Schneider; Bruce Stadel; Eric Colman
Journal:  BMJ       Date:  2002-05-18

2.  Engraftment and bone mass are enhanced by PTHrP 1-34 in ectopically transplanted vertebrae (vossicle model) and can be non-invasively monitored with bioluminescence and fluorescence imaging.

Authors:  Blake Eason Hildreth; Michelle M Williams; Katarzyna A Dembek; Krista M Hernon; Thomas J Rosol; Ramiro E Toribio
Journal:  Transgenic Res       Date:  2015-08-14       Impact factor: 2.788

Review 3.  Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.

Authors:  Jean-Yves Reginster
Journal:  Drugs       Date:  2011-01-01       Impact factor: 9.546

4.  Targeted deletion of histidine decarboxylase gene in mice increases bone formation and protects against ovariectomy-induced bone loss.

Authors:  L A Fitzpatrick; E Buzas; T J Gagne; A Nagy; C Horvath; V Ferencz; A Mester; B Kari; M Ruan; A Falus; J Barsony
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-25       Impact factor: 11.205

5.  Osteosarcoma associated with hyperparathyroidism.

Authors:  Paul C Jutte; Renato Rosso; Massimiliano de Paolis; Costatino Errani; Elisabetta Pasini; Laura Campanacci; Gaetano Bacci; Franco Bertoni; Mario Mercuri
Journal:  Skeletal Radiol       Date:  2004-05-25       Impact factor: 2.199

6.  Profile of teriparatide in the management of postmenopausal osteoporosis.

Authors:  Andrea Sikon; Pelin Batur
Journal:  Int J Womens Health       Date:  2010-08-09

7.  Sost down-regulation by mechanical strain in human osteoblastic cells involves PGE2 signaling via EP4.

Authors:  Gabriel L Galea; Andrew Sunters; Lee B Meakin; Gul Zaman; Toshihiro Sugiyama; Lance E Lanyon; Joanna S Price
Journal:  FEBS Lett       Date:  2011-06-28       Impact factor: 4.124

Review 8.  Potentials of Neuropeptides as Therapeutic Agents for Neurological Diseases.

Authors:  Xin Yi Yeo; Grace Cunliffe; Roger C Ho; Su Seong Lee; Sangyong Jung
Journal:  Biomedicines       Date:  2022-02-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.